GIPLOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Global Innovative Platforms Inc.

Global Innovative Platforms Inc. is a U.S.-based development-stage company focused on breath analysis and air-quality technologies for animal health and related diagnostics. Its core platform technologies, VOCAM Plus and FROG, combine gas chromatography and AI software to detect disease markers, assess treatment effectiveness, and identify potentially toxic environmental or food conditions.

Ask about the company
Revenue0.0m USD
Operating profit (EBIT)-0.7m USD
−427.4 %y/y
Net income-0.7m USD
−427.4 %y/y
Free cash flow-0.6m USD
−541.7 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-0.8-0.6-0.4-0.20.0m USD2021: 0.00 m USD2021: EBIT -0.07 m USD20212022: 0.00 m USD2022: EBIT -0.05 m USD20222023: 0.00 m USD2023: EBIT -0.28 m USD20232024: 0.00 m USD2024: EBIT -0.14 m USD20242025: 0.00 m USD2025: EBIT -0.72 m USD20250.00-0.72
RevenueOperating profit (EBIT)

Business

Share of revenue
Diagnostic technology platforms60 %

Core breath and air analysis systems used to detect biomarkers and assess health conditions.

Technology licensing25 %

Licensing arrangements that monetize proprietary technology and know-how.

Research and development services15 %

Internal and collaborative development work to expand applications and improve product readiness.

Customers

The company appears to sell primarily into animal health and adjacent diagnostic use cases, with a focus on buyers that need non-invasive detection tools. Based on its disclosures, customers likely include veterinary and animal-health partners, licensing counterparties, and potential collaborators that can commercialize the technology. It also targets users interested in environmental or food-condition screening where breath or air analysis can provide early warning signals.

Animal health partners

Veterinary and animal-health organizations that would use breath-analysis tools to detect disease or monitor treatment effectiveness.

Licensing counterparties

Third parties that license the company's technology and know-how to commercialize products or applications.

Research and collaboration partners

Organizations that fund or co-develop applications for VOC detection and related diagnostics.

Environmental and food-safety users

Potential end users of air-analysis tools for toxic environmental or food-condition detection.

Strategy

Management is focused on securing capital, advancing product development, and moving the breath-analysis platform toward commercialization. The company also references a plan to merge with another entity with experienced management and growth opportunities, suggesting a capital-formation and transaction-driven strategy. In the near term, execution depends on funding availability and on converting technology development into licensing or product revenue.

Secure additional financingShort term

The company has limited operating cash generation and needs external funding to continue development.

Commercialize breath-analysis technologyMedium term

Revenue depends on turning VOCAM Plus and FROG into market-ready products or licensed solutions.

Pursue strategic transaction opportunitiesMedium term

Management has indicated a plan to merge with an entity that brings experienced management and growth opportunities.

Geography

The company is headquartered in the United States and reports in U.S. dollars under U.S. GAAP. The available excerpts do not disclose a meaningful geographic revenue split, and the business appears to be at an early commercialization stage with limited operating footprint. As a result, geography currently matters more as a funding and regulatory base than as a diversified revenue driver.

Risks

The company is a development-stage business with substantial going-concern risk, limited revenue, and dependence on outside financing. Its technology also relies on licensed intellectual property, and expired patents could weaken exclusivity and pricing power. Competitive, regulatory, and execution risks are elevated because the business is still proving product-market fit and has not established a stable commercial base.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Going-concern and liquidity risk1Dependence on licensed intellectual property2Financing dilution3Commercialization and adoption risk4Competitive disadvantage5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Going-concern and liquidity riskImpact: CriticalLikelihood: High

    Auditors noted substantial doubt about the company's ability to continue as a going concern, and operations depend on new capital.

    Exposure: Ongoing operating losses and limited revenue

  2. Dependence on licensed intellectual propertyImpact: HighLikelihood: High

    The business relies on Defiant Technologies' VOCAM Plus license, and expired patents may allow competitors to replicate the technology.

    Exposure: VOCAM Plus commercialization

  3. Financing dilutionImpact: HighLikelihood: High

    Future funding is expected to come from equity or convertible instruments, which can dilute existing shareholders.

    Exposure: Capital raises and strategic transactions

  4. Commercialization and adoption riskImpact: HighLikelihood: High

    The company has limited revenue and no approved products for sale, so demand and regulatory progress remain uncertain.

    Exposure: Animal-health diagnostics and licensing

  5. Competitive disadvantageImpact: MediumLikelihood: High

    Management discloses limited financial and personnel resources versus established competitors.

    Exposure: Product development and commercialization

Accounting

Judgemental items
Revenue recognition for licensing arrangements

Revenue is currently small and appears tied to technology licensing, so contract terms and timing matter.

Impact: Can create quarter-to-quarter volatility in reported revenue

Research and development expense recognition

Development-stage costs are being incurred before commercialization and are likely expensed as incurred.

Impact: Suppresses near-term earnings and reflects product-readiness risk

Long-lived asset and intangible impairment

Pre-commercial businesses with uncertain cash flows face higher impairment risk on capitalized assets or acquired rights.

Impact: Could cause non-cash charges if expected commercialization weakens

Going-concern and financing disclosures

The company depends on external funding and has disclosed substantial doubt about continuation.

Impact: Important for assessing solvency, dilution, and survival risk

Similar listed companies

Publicly listed companies with a comparable business focus.

Global Gas Corp

HGASW · Industrial Inorganic Chemicals

Harvard Bioscience, Inc

HBIO · Laboratory Analytical Instruments

Co-Diagnostics, Inc.

CODX · Surgical & Medical Instruments & Apparatus

Global Technologies LTD

GTLL · Radio & Tv Broadcasting & Communications Equipment

Intelligent Bio Solutions Inc

INBS · Surgical & Medical Instruments & Apparatus

Greenland Mines Ltd

GRMLW · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026